Career

Guru Sonpavde: Job opportunity for a medical oncologist to join AdventHealth Central Florida’s GU Program

adventhealth.com

Dec 2, 2024, 13:05

Guru Sonpavde: Job opportunity for a medical oncologist to join AdventHealth Central Florida’s GU Program

Guru Sonpavde, Oncology and Phase I Clinical Trials Director at AdventHealth Central Florida, shared a post on LinkedIn:

“We are Hiring!

Exciting job opportunity for a medical oncologist to join us at AdventHealth Central Florida (Orlando metro area) to support the rapidly growing

GU medical oncology Program with a prostate cancer focus involving collaboration with one of the top robotic prostatectomy surgeons in the world,
Developmental Therapeutics Phase I clinical trial Program across solid tumors, while
maintaining a Hematology-Oncology Practice that can be tailored.

We have

multidisciplinary tumor boards including molecular tumor boards,
Teaching Program with Internal Medicine Residency,
potential of affiliation and appointment in a Medical School,
a growing portfolio of clinical trials that have led to several recent co-authorships in major oral presentations, as well as investigator initiated trials in a rapidly growing and diverse region of the country and
opportunities to develop the real-world database for translational research projects!

This opportunity is an especially well-suited robust opportunity for an ambitious junior investigator motivated to conduct clinical trials under mentorship in an academic practice setting and support the prostate cancer and Phase I trial Program!”

Read further.

More posts featuring Guru Sonpavde.

Dr. Guru Sonpavde is the Oncology and Phase I Clinical Trials Director at AdventHealth Central Florida and the Chair of Bladder Cancer Research. He is also a Professor of Medicine at the University of Central Florida.

His primary focus is drug development, leading innovative clinical trials on novel immunotherapies and targeted therapies for genitourinary cancers, especially bladder cancer, along with prostate, kidney, penile, and testicular cancers.